Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-mutated advanced NSCLC in China
Expert Review of Pharmacoeconomics & Outcomes Research · 03.07.2026 · 26 (6) · 813-822
DOI: 10.1080/14737167.2026.2691180 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 10.07.2026. Verfasst von Jing He und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- School of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, J., Yu, J., Liu, R., & Yang, Q. (2026). Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-mutated advanced NSCLC in China. Expert Review of Pharmacoeconomics & Outcomes Research, 26(6), 813-822. https://doi.org/10.1080/14737167.2026.2691180
Vancouver
He J, Yu J, Liu R, Yang Q. Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-mutated advanced NSCLC in China. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(6):813-822. doi:10.1080/14737167.2026.2691180
BibTeX
@article{He2026,
author = {He, Jing and Yu, Jialin and Liu, Ruixuan and Yang, Qing},
title = {Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-mutated advanced NSCLC in China},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {6},
pages = {813--822},
doi = {10.1080/14737167.2026.2691180}
}
EUVIMED